DOCSLIB.ORG

Ocular Effects of Serotonin Antidepressants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ocular Effects of Serotonin Antidepressants Graylands Hospital Drug Bulletin Ocular Effects of Serotonin Antidepressants North Metropolitan Health Service - Mental Health October 2016 Vol 23 No. 2 ISSN 1323 -1251 Although there is a vast body of literature Summary published about side effects of psychotropic medications and serotonergic medications in SSRIs have been shown to have a higher particular, when it comes to visual prevalence for dry eye than SNRIs. disturbance, the studies seldom describe the visual effects in detail; they only mention TCAs, SSRIs and SNRIs have all been vague terms such as ‘visual disturbances’ or 1 reported to precipitate acute angle-closure ‘visual symptoms’. There is also a tendency for only the more serious effects to be glaucoma reported rather than all levels of visual disturbance. 2 A 2007 paper looking at specific SSRIs and SNRIs may cause mydriasis by side effects causing discontinuation of noradrenergic effects or anticholinergic Selective Serotonin Reuptake Inhibitors effects or by 5-HT 7 effects which can cause (SSRIs) listed ‘visual change’ as the 10 th relaxation of the sphincter muscle of the most likely cause of discontinuation ahead of pupil headaches. 2 Mirtazapine, moclobemide and trazodone Table 1 (at the end of the article) shows the have been reported to cause mydriasis information presented in the Australian Medicines Handbook (AMH) and MIMS TCAs and Antipsychotics have been regarding ocular side effects to be relatively reported to cause accommodation vague and not particularly useful when faced with a clinical situation where your patient is interference by anticholinergic effects complaining of a specific side effect like Reports of SSRI induced EPSEs can, rarely, ‘blurred vision’ and an alternative antidepressant is desired. affect ocular muscles and lead to visual symptoms. To decide which antidepressant is most forgiving regarding visual disturbance, the SSRIs have been linked to optic neuropathy, underlying cause of the visual disturbance possibly via multiple transient vasospasms in should first be considered. Mechanisms of the optic nerve which could progressively medication induced ‘blurred vision’ could be induce ischaemic optic neuropathy. varied including: • Eyelid and keratoconjunctival disorders Dry Eye • Uveal tract disorders • Accommodation interference An association between antidepressant use, • Glaucoma (specifically angle-closure particularly tricyclic antidepressants and glaucoma) . SSRIs, and dry eye, with decreased lacrimal • secretion being the likely mechanism, has Cataract and pigmentary deposits in 3 the lens and cornea been reported in several studies. Animal • Retinal abnormalities/retinopathy studies have suggested several mechanisms: • Dystonia of ocular musculature/oculogyric crisis Graylands Hospital Drug Bulletin April 2016 Vol 23 No.2 Page 1 • Parasympathetic denervation of the muscle of the eye and subsequent human lacrimal gland may cause mydriasis. 9 In patients with a biometric reduced tear flow predisposition to an occludable angle, the • Neuronal release of serotonin (5-HT) further reduction in the width of the may be involved in regulation of iridocorneal angle induced by mydriasis may lacrimal secretions block circulation of the aqueous humour with 9 • Chronic exposure to histamine and 5- the possible development of glaucoma. HT altered the secretory process Stimulation of 5-HT 1A receptors reduces IOP SSRIs have been shown to have a higher and reduces the rate of production of prevalence for dry eye than Serotonin and aqueous humour. This counterbalances the Noradrenaline Reuptake Inhibitors (SNRIs) effect of stimulation of 5-HT 7 which increases 9 despite the SNRIs having more aqueous humour production. Theoretically 3 anticholinergic effects. then, vortioxetine, which is a 5-HT 1A agonist and a 5-HT 7 antagonist, should prove It has been proposed that altered levels of beneficial to raised IOP. serotonin due to SSRI treatment can affect the sensitivity thresholds of corneal nerves, 5-HT 2A/2C receptors are also expressed in the resulting in disruption to tear film which ICB but the effect on IOP has not been fully 4 covers the ocular surface. Serotonin has elucidated. The known effects of 5-HT 2C been detected in human tears, and may stimulation on fluid balance could be a affect corneal nociceptor sensitisation. plausible mechanism for SSRI effects on IOP. Changes in serotonin levels in tears could be The increase in IOP caused by fluoxetine in associated with specific dry eye subtypes.5 rabbits has been inhibited by the selective 5- 9 HT 2A antagonist ketanserin. Other proposed mechanisms for increase Glaucoma pressure include ciliochoroidal effusion or an immune reaction in choroidal tissue. 10 Tricyclic antidepressants (TCAs) and SSRIs However, Murphy et al makes the point that e.g., citalopram, escitalopram, fluoxetine and many drugs with probable Naranjo scores are paroxetine and the SNRI venlafaxine, have involved in serotonin and dopamine been reported to precipitate acute angle- metabolism. 10 Interestingly, although there closure glaucoma. There have also been are case reports of glaucoma associated with case reports of other antidepressants bupropion use, Kimat et al report a significant precipitating acute angle-closure e.g. inverse association with bupropion use and 6 mirtazapine. glaucoma.11 Their explanation is that bupropion may be protective against the The underlying mechanism is pupillary block development of glaucoma through inhibition caused by pupil dilatation, which is attributed 11 of TNF-alpha. to the significant anticholinergic and serotonergic side effects of these Clinicians should consider referring patients 6-8 antidepressants. The role of serotonin in at increased risk of acute angle-closure human ocular physiology has yet to be fully glaucoma for an ophthalmic assessment prior determined, however, serotonin is known to to prescribing SSRIs. 8 be an effector on various smooth muscle including the ciliary muscle and sphincter of the eye. 9 Dysfunction of the serotonin system has been implicated in intra ocular pressure (IOP) modifications. It is believed that serotonin 5-HT 1A , 5-HT 2A/2C and 5-HT 7 receptors are located at the level of the iris- ciliary body (ICB) complex but only 5-HT 7 receptors have been identified at the level of iris musculature. These receptors are responsible for relaxation of the sphincter Graylands Hospital Drug Bulletin April 2016 Vol 23 No.2 Page 2 Table 2 Bazire’s Recommendations for Antidepressants in Patients with Glaucoma 12 Although SSRIs primarily act as antidepressants by inhibition of reuptake of Lower Risk Moderate Higher serotonin in the central nervous system Risk Risk (CNS), they also lead to increases in Agomelatine Duloxetine Tricyclics available serotonin in other areas of the body Bupropion Mirtazapine such as blood and eye. Some SSRIs also MAOIs SSRIs have effects on dopamine, cholinergic and Moclobemide Venlafaxine adrenergic receptors. The serotonin receptors Trazodone thought to be involved in the dynamics of intraocular pressure in the eye are 5-HT 1A , 5- Vortioxetine 1 HT 2A , 5HT 2C and 5-HT 7. Patients with narrow angle glaucoma can be SSRIs may cause mydriasis by noradrenergic prescribed anticholinergic medication effects or anticholinergic effects or by 5-HT 7 effects which can cause relaxation of the provided intraocular pressure is monitored. 1 The main symptoms of narrow angle sphincter muscle of the pupil. glaucoma are blurred vision, coloured halos Mydriasis around bright lights, intense pain, lacrimation, 12 lid oedema, red eye, nausea and vomiting. Dilation of the pupil of the eye, especially when excessive or prolonged, is usually as a result of trauma, a medical disorder or a drug. Uveal Tract Effects Antidepressants that can cause dilation of the The uveal tract is a layer of tissue located pupil include SSRIs, mirtazapine, moclobemide and trazodone. 12 Mydriasis has between the outer layer (cornea and sclera) 12 and the inner layer (the retina) of the eye. been reported with duloxetine. The front portion (anterior) of the uveal tract This effect does not seem to cause major contains the iris, and the back portion visual discomfort or problems, unless it (posterior) of the uveal tract contains the becomes associated with a dramatic increase choroid and the stroma of the ciliary body. in IOP and with eventual glaucoma attacks. The mydriatic effects of SSRIs are likely to be reversible after cessation of therapy, Figure 1. Structure of the eye with the uveal tract labelled red. especially if they do not become complicated The uvea can be divided into three parts: the iris, the ciliary 1 body, and the choroids. 13 by angle-closure glaucoma. Accommodation Interference TCAs and antipsychotics have been reported to cause visual accommodation interference via their anticholinergic effects. 1 No reports of SSRIs or SNRIs having this effect were found. Since some of the SSRIs do have significant anticholinergic effects e.g. fluoxetine, it should be expected that accommodation difficulties could be caused by fluoxetine. Cataract and Pigmentary Deposits in the Lens and Cornea Reviews considering causes of ocular adverse effects are concerned firstly with photosensitivity e.g. chlorpromazine and then Graylands Hospital Drug Bulletin April 2016 Vol 23 No.2 Page 3 the effects of atypical antipsychotics. Antidepressants generally were not mentioned. Other Reported Ocular Side Effects Retinal Abnormalities/Retinopathy SSRIs have been linked to optic neuropathy. 16 The proposed mechanism
Load more

Recommended publications
  • Formulary and Prescribing Guidelines
    Formulary and Prescribing Guidelines SECTION 1: TREATMENT OF DEPRESSION Section 1. Treatment of depression 1.1 Introduction This guidance should be considered as part of a stepped care approach in the management of depressive disorders. Antidepressants are not routinely recommended for persistent sub-threshold depressive symptoms or mild depression but can be considered in these categories where there is a past history of moderate or severe depression, initial presentation of sub-threshold depressive symptoms for at least 2 years, and persistence of either mild or sub-threshold depression after other interventions1 have failed. The most current NICE guidance should be consulted wherever possible to obtain the most up to date information. For individuals with moderate or severe depression, a combination of antidepressant medication and a high intensity psychological intervention (CBT or IPT) is recommended. When depression is accompanied by symptoms of anxiety, usually treat the depression first. If the person has an anxiety disorder and co-morbid depression or depressive symptoms, consider treating the anxiety first. Also consider offering advice on sleep hygiene, by way of establishing regular sleep and wake times; avoiding excess eating, avoiding smoking and drinking alcohol before sleep; and taking regular physical exercise if possible. Detailed information on the treatment of depression in children and adolescents can be found in section 12. Further guidance on prescribing for older adults and for antenatal/postnatal service users can be found in section 11 and section 20, respectively. 1.2 Approved Drugs for the treatment of Depression in Adults For licensing indications, see Annex 1 Drug5 Formulation5 Comments2,3,4 Caps 20mg, 60mg Selective serotonin reuptake inhibitor (SSRI) Fluoxetine Liquid 20mg/5ml 1st line SSRI (based on acquisition cost) Tabs 10mg, 25mg, 50mg Amitriptyline Tricyclic (TCA).
    [Show full text]
  • Dosulepin Prescribing
    SAFETY BULLETIN: DOSULEPIN PRESCRIBING In December 2007, the Medicines and Healthcare Regulatory Agency (MHRA) issued safety advice around prescribing of dosulepin, related to the narrow margin between therapeutic doses and potentially fatal doses. Nevertheless, dosulepin continues to be prescribed widely. Over eight years after the safety advice was published, prescribing of dosulepin in the Dorset area remains high. In the South West area, Dorset CCG was the highest prescriber of dosulepin for the 2015/16 financial year (3.238% of all antidepressant items). Of the 209 CCGs in the UK, Dorset is the fourteenth highest prescriber of dosulepin, and well above the national average of 2.111%. The following points summarise the reasons that dosulepin is not recommended for prescribing nationally, and in Dorset: Dosulepin has a small margin of safety between the (maximum) therapeutic dose and potentially fatal doses. The NICE guideline on depression in adults recommends that dosulepin should not be prescribed for adults with depression because evidence supporting its tolerability relative to other antidepressants is outweighed by the increased cardiac risk and toxicity in overdose. Dosulepin has also been used ‘off label’ in other indications such as fibromyalgia and neuropathic pain. However the evidence for use in in this way is weak, and is not recommended. The lethal dose of dosulepin is relatively low and can be potentiated by alcohol and other CNS depressants. Dosulepin overdose is associated with high mortality and can occur rapidly, even before hospital treatment can be received. Onset of toxicity occurs within 4-6 hours. Every year, up to 200 people in England and Wales fatally overdose with dosulepin.
    [Show full text]
  • Dose Equivalents of Antidepressants Evidence-Based Recommendations
    Journal of Affective Disorders 180 (2015) 179–184 Contents lists available at ScienceDirect Journal of Affective Disorders journal homepage: www.elsevier.com/locate/jad Research report Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials Yu Hayasaka a,n, Marianna Purgato b, Laura R Magni c, Yusuke Ogawa a, Nozomi Takeshima a, Andrea Cipriani b,d, Corrado Barbui b, Stefan Leucht e, Toshi A Furukawa a a Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Yoshida Konoe-cho, Sakyo- ku, Kyoto 606-8501, Japan b Department of Public Health and Community Medicine, Section of Psychiatry, University of Verona, Policlinico “G.B.Rossi”, Pzz.le L.A. Scuro, 10, Verona 37134, Italy c Psychiatric Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Italy d Department of Psychiatry, University of Oxford, Oxford, UK e Department of Psychiatry and Psychotherapy, Technische Universität München, Klinikum rechts der Isar, Ismaningerstr. 22, 81675 Munich, Germany article info abstract Article history: Background: Dose equivalence of antidepressants is critically important for clinical practice and for Received 4 February 2015 research. There are several methods to define and calculate dose equivalence but for antidepressants, Received in revised form only daily defined dose and consensus methods have been applied to date. The purpose of the present 10 March 2015 study is to examine dose equivalence of antidepressants by a less arbitrary and more systematic method. Accepted 12 March 2015 Methods: We used data from all randomized, double-blind, flexible-dose trials comparing fluoxetine or Available online 31 March 2015 paroxetine as standard drugs with any other active antidepressants as monotherapy in the acute phase Keywords: treatment of unipolar depression.
    [Show full text]
  • Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review
    pharmaceuticals Article Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review Marcin Siwek 1,*, Adrian Andrzej Chrobak 2 , Aleksandra Gorostowicz 3, Anna Julia Krupa 3 and Dominika Dudek 2 1 Department of Affective Disorders, Jagiellonian University Medical College, Kopernika Street 21a, 31-501 Kraków, Poland 2 Department of Adult Psychiatry, Jagiellonian University Medical College, Kopernika Street 21a, 31-501 Kraków, Poland; [email protected] (A.A.C.); [email protected] (D.D.) 3 Department of Psychiatry, Jagiellonian University Medical College, Kopernika Street 21a, 31-501 Kraków, Poland; [email protected] (A.G.); [email protected] (A.J.K.) * Correspondence: [email protected]; Tel.: +48-12-424-87-00 Abstract: The efficacy of vortioxetine has been proven in many studies, but data concerning dis- continuation symptoms (DS) after vortioxetine withdrawal is scarce. The aim of our study is to systematically evaluate the prevalence, determinants, and clinical features of vortioxetine DS in a retrospective chart review. Data were obtained from medical records of 263 adult patients with depressive disorders who discontinued former vortioxetine treatment. DS were observed in eight (3%) patients after 71–375 days (median 272) of treatment. DS emerged after median three days following vortioxetine withdrawal and lasted for median seven days. The clinical presentation of DS involved: emotional lability (100% of patients), irritability (75%), sudden worsening of mood (75%), nervousness (37.5%), and agitation (37.5%). Median DESS score was four (range of four to six). DS Citation: Siwek, M.; Chrobak, A.A.; were significantly more prevalent after accidental vs.
    [Show full text]
  • Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)
    Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine
    [Show full text]
  • Differentiate Red Eye Disorders
    Introduction DIFFERENTIATE RED EYE DISORDERS • Needs immediate treatment • Needs treatment within a few days • Does not require treatment Introduction SUBJECTIVE EYE COMPLAINTS • Decreased vision • Pain • Redness Characterize the complaint through history and exam. Introduction TYPES OF RED EYE DISORDERS • Mechanical trauma • Chemical trauma • Inflammation/infection Introduction ETIOLOGIES OF RED EYE 1. Chemical injury 2. Angle-closure glaucoma 3. Ocular foreign body 4. Corneal abrasion 5. Uveitis 6. Conjunctivitis 7. Ocular surface disease 8. Subconjunctival hemorrhage Evaluation RED EYE: POSSIBLE CAUSES • Trauma • Chemicals • Infection • Allergy • Systemic conditions Evaluation RED EYE: CAUSE AND EFFECT Symptom Cause Itching Allergy Burning Lid disorders, dry eye Foreign body sensation Foreign body, corneal abrasion Localized lid tenderness Hordeolum, chalazion Evaluation RED EYE: CAUSE AND EFFECT (Continued) Symptom Cause Deep, intense pain Corneal abrasions, scleritis, iritis, acute glaucoma, sinusitis, etc. Photophobia Corneal abrasions, iritis, acute glaucoma Halo vision Corneal edema (acute glaucoma, uveitis) Evaluation Equipment needed to evaluate red eye Evaluation Refer red eye with vision loss to ophthalmologist for evaluation Evaluation RED EYE DISORDERS: AN ANATOMIC APPROACH • Face • Adnexa – Orbital area – Lids – Ocular movements • Globe – Conjunctiva, sclera – Anterior chamber (using slit lamp if possible) – Intraocular pressure Disorders of the Ocular Adnexa Disorders of the Ocular Adnexa Hordeolum Disorders of the Ocular
    [Show full text]
  • Peripapillary Retinal Vascular Involvement in Early Post-COVID-19 Patients
    Journal of Clinical Medicine Article Peripapillary Retinal Vascular Involvement in Early Post-COVID-19 Patients 1,2, 1,2, 1,2, Alfonso Savastano y , Emanuele Crincoli y , Maria Cristina Savastano * , Saad Younis 3, Gloria Gambini 1,2, Umberto De Vico 1,2 , Grazia Maria Cozzupoli 1,2 , Carola Culiersi 1,2 , Stanislao Rizzo 1,2,4 and Gemelli Against COVID-19 Post-Acute Care Study Group 2 1 Ophthalmology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00196 Rome, Italy; [email protected] (A.S.); [email protected] (E.C.); [email protected] (G.G.); [email protected] (U.D.V.); [email protected] (G.M.C.); [email protected] (C.C.); [email protected] (S.R.) 2 Department of Ophthalmology, Catholic University of “Sacro Cuore”, 00168 Rome, Italy 3 Department of Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London NW1 5QH, UK; [email protected] 4 Neuroscience Institute, Consiglio Nazionale delle Ricerche, Istituto di Neuroscienze, 56124 Pisa, Italy * Correspondence: [email protected]; Tel.: +39-063-015-4928 These authors contributed equally to this work. y Received: 5 August 2020; Accepted: 3 September 2020; Published: 8 September 2020 Abstract: The ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-20s) to cause multi-organ ischemia and coronavirus-induced posterior segment eye diseases in mammals gave concern about potential sight-threatening ischemia in post coronavirus disease 2019 patients. The radial peripapillary capillary plexus (RPCP) is a sensitive target due to the important role in the vascular supply of the peripapillary retinal nerve fiber layer (RNFL).
    [Show full text]
  • Cranial Nerve Palsy
    Cranial Nerve Palsy What is a cranial nerve? Cranial nerves are nerves that lead directly from the brain to parts of our head, face, and trunk. There are 12 pairs of cranial nerves and some are involved in special senses (sight, smell, hearing, taste, feeling) while others control muscles and glands. Which cranial nerves pertain to the eyes? The second cranial nerve is called the optic nerve. It sends visual information from the eye to the brain. The third cranial nerve is called the oculomotor nerve. It is involved with eye movement, eyelid movement, and the function of the pupil and lens inside the eye. The fourth cranial nerve is called the trochlear nerve and the sixth cranial nerve is called the abducens nerve. They each innervate an eye muscle involved in eye movement. The fifth cranial nerve is called the trigeminal nerve. It provides facial touch sensation (including sensation on the eye). What is a cranial nerve palsy? A palsy is a lack of function of a nerve. A cranial nerve palsy may cause a complete or partial weakness or paralysis of the areas served by the affected nerve. In the case of a cranial nerve that has multiple functions (such as the oculomotor nerve), it is possible for a palsy to affect all of the various functions or only some of the functions of that nerve. What are some causes of a cranial nerve palsy? A cranial nerve palsy can occur due to a variety of causes. It can be congenital (present at birth), traumatic, or due to blood vessel disease (hypertension, diabetes, strokes, aneurysms, etc).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0179214 A1 Dubé Et Al
    US 20100179214A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0179214 A1 Dubé et al. (43) Pub. Date: Jul. 15, 2010 (54) DOXEPIN TRANS ISOMERS AND SOMERC continuation-in-part of application No. 1 1/804,720, MIXTURES AND METHODS OF USING THE filed on May 18, 2007. SAME TO TREAT SLEEP DSORDERS (60) Provisional application No. 60/898,378, filed on Jan. (75) Inventors: Susan E. Dubé, Carlsbad, CA (US); 30, 2007, provisional application No. 60/801,824, Neil B. Kavey, Chappaqua, NY filed on May 19, 2006, provisional application No. (US) 60/833,319, filed on Jul 25, 2006. Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP Publication Classification 2040 MAINSTREET, FOURTEENTH FLOOR (51) Int. Cl. IRVINE, CA 92.614 (US) A63L/335 (2006.01) A6IP 25/20 (2006.01) (73) Assignee: SOMAXON PHARMACEUTICALS, INC., (52) U.S. Cl. ........................................................ S14/450 San Diego, CA (US) (21) Appl. No.: 12/535,623 (57) ABSTRACT The invention relates to use of the trans-(E) isomer or iso (22) Filed: Aug. 4, 2009 meric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, phar Related U.S. Application Data maceutically-acceptable salts of doxepin and prodrugs of the (63) Continuation-in-part of application No. 12/022,788, same; compositions containing the same, for the treatment of filed on Jan. 30, 2008, now abandoned, which is a sleep disorders US 2010/0179214 A1 Jul. 15, 2010 DOXEPIN TRANS ISOMERS AND SOMERC brings scrutiny from the Drug Enforcement Administration MIXTURES AND METHODS OF USING THE and other regulatory bodies, and requires registration and SAME TO TREAT SLEEP DSORDERS administrative controls in physicians offices.
    [Show full text]
  • Supranuclear and Internuclear Ocular Motility Disorders
    CHAPTER 19 Supranuclear and Internuclear Ocular Motility Disorders David S. Zee and David Newman-Toker OCULAR MOTOR SYNDROMES CAUSED BY LESIONS IN OCULAR MOTOR SYNDROMES CAUSED BY LESIONS OF THE MEDULLA THE SUPERIOR COLLICULUS Wallenberg’s Syndrome (Lateral Medullary Infarction) OCULAR MOTOR SYNDROMES CAUSED BY LESIONS OF Syndrome of the Anterior Inferior Cerebellar Artery THE THALAMUS Skew Deviation and the Ocular Tilt Reaction OCULAR MOTOR ABNORMALITIES AND DISEASES OF THE OCULAR MOTOR SYNDROMES CAUSED BY LESIONS IN BASAL GANGLIA THE CEREBELLUM Parkinson’s Disease Location of Lesions and Their Manifestations Huntington’s Disease Etiologies Other Diseases of Basal Ganglia OCULAR MOTOR SYNDROMES CAUSED BY LESIONS IN OCULAR MOTOR SYNDROMES CAUSED BY LESIONS IN THE PONS THE CEREBRAL HEMISPHERES Lesions of the Internuclear System: Internuclear Acute Lesions Ophthalmoplegia Persistent Deficits Caused by Large Unilateral Lesions Lesions of the Abducens Nucleus Focal Lesions Lesions of the Paramedian Pontine Reticular Formation Ocular Motor Apraxia Combined Unilateral Conjugate Gaze Palsy and Internuclear Abnormal Eye Movements and Dementia Ophthalmoplegia (One-and-a-Half Syndrome) Ocular Motor Manifestations of Seizures Slow Saccades from Pontine Lesions Eye Movements in Stupor and Coma Saccadic Oscillations from Pontine Lesions OCULAR MOTOR DYSFUNCTION AND MULTIPLE OCULAR MOTOR SYNDROMES CAUSED BY LESIONS IN SCLEROSIS THE MESENCEPHALON OCULAR MOTOR MANIFESTATIONS OF SOME METABOLIC Sites and Manifestations of Lesions DISORDERS Neurologic Disorders that Primarily Affect the Mesencephalon EFFECTS OF DRUGS ON EYE MOVEMENTS In this chapter, we survey clinicopathologic correlations proach, although we also discuss certain metabolic, infec- for supranuclear ocular motor disorders. The presentation tious, degenerative, and inflammatory diseases in which su- follows the schema of the 1999 text by Leigh and Zee (1), pranuclear and internuclear disorders of eye movements are and the material in this chapter is intended to complement prominent.
    [Show full text]
  • Albinism Terminology
    Albinism Terminology Oculocutaneous Albinism (OCA): Oculocutaneous (pronounced ock-you-low-kew- TAIN-ee-us) Albinism is an inherited genetic condition characterized by the lack of or diminished pigment in the hair, skin, and eyes. Implications of this condition include eye and skin sensitivities to light and visual impairment. Ocular Albinism (OA): Ocular Albinism is an inherited genetic condition, diagnosed predominantly in males, characterized by the lack of pigment in the eyes. Implications of this condition include eye sensitivities to light and visual impairment. Hermansky Pudlak Syndrome (HPS): Hermansky-Pudlak Syndrome is a type of albinism which includes a bleeding tendency and lung disease. HPS may also include inflammatory bowel disease or kidney disease. The severity of these problems varies much from person to person, and the condition can be difficult to diagnose with traditional blood tests Chediak Higashi Syndrome: Chediak Higashi Syndrome is a type of albinism in which the immune system is affected. Illnesses and infections are common from infancy and can be severe. Issues also arise with blood clotting and severe bleeding. Melanin: Melanin is pigment found in a group of cells called melanocytes in most organisms. In albinism, the production of melanin is impaired or completely lacking. Nystagmus: Nystagmus is an involuntary movement of the eyes in either a vertical, horizontal, pendular, or circular pattern caused by a problem with the visual pathway from the eye to the brain. As a result, both eyes are unable to hold steady on objects being viewed. Nystagmus may be accompanied by unusual head positions and head nodding in an attempt to compensate for the condition.
    [Show full text]
  • List of Vital Essential and Necessary Drugs and Medical Sundries For
    LIST OF VITAL ESSENTIAL AND NECESSARY DRUGS AND 2015 MEDICAL SUNDRIES FOR PUBLIC HEALTH INSTITUTIONS Sixth Edition STANDARDS & REGULATION DIVISION JAMAICA List of Vital Essential and Necessary List of Drugs and Medical Sundries for Public Institutions List of Vital Essential and Necessary List of Drugs and Medical Sundries for Public Institutions CONTENTS CONTENTS Contd. Page Preface 5-6 Page Information on Hospitals and Health Centres 7 Explanatory Notes 8 Medical Sundries 69-73 Prescription Writing 9-10 Dental Supplies 74 Algorithm for Treatment of Hypertension 11-12 Radiotherapy – Diagnostic Agents 75 Algorithm for Management of Type 2 Diabetes 13-14 Raw Materials 76 List of Drugs Designated for NHF 15-17 List of Drugs Designated for JADEP 18 VOLUME11 – SPECIALIST LIST 77 VOLUME 1 – GENERAL LIST 19 CLASSIFICATION OF DRUGS SECTION 1. Cardiovascular System 78 CLASSIFICATION OF DRUGS SECTION 2. Central Nervous System 79 SECTION 1. Cardiovascular System 20-24 SECTION 3. Dermatology 80 SECTION 2. Central Nervous System 25-30 SECTION 4. Endocrine System 80 SECTION 3. Dermatology 31-33 SECTION 5. Gastro-intestinal System 81 SECTION 4. Ear, Nose and Oropharynx 34-35 SECTION 6. Infections 81 SECTION 5. Endocrine System 36-38 SECTION 7. Malignant Disease and SECTION 6. Gastro-intestinal System 39-40 Immunosuppression 82 SECTION 7. Infections 41-46 SECTION 8. Musculoskeletal and Joint Diseases 83 SECTION 8. Malignant Disease and SECTION 9. Ophthalmology 83 Immunosuppression 47-49 SECTION 10. Genito-Urinary Tract Disorders 84 SECTION 9. Musculoskeletal and Joint Diseases 50-51 SECTION 11. Respiratory System 84 SECTION 10. Nutrition and Blood 52-54 SECTION 12.
    [Show full text]